Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Study uncovers important genetic predispositions for acute myeloid leukemia

The National Center for Tumor Diseases Dresden is a joint institution of the German Cancer Research Center, the University Hospital Carl Gustav Carus Dresden, Carl Gustav Carus Faculty of Medicine at TU Dresden and the Helmholtz-Zentrum Dresden-Rossendorf.

24 Nov 2021

Donor cells with clonal hematopoiesis may improve bone marrow transplant outcomes

Clonal hematopoiesis, a condition in which mutations associated with blood cancers are found in the blood of healthy people, is common with aging.

22 Nov 2021

Experts develop a functional precision medicine approach to assign therapies to cancer patients

A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients' cells can be clinically useful in patients with aggressive hematological cancers.

18 Nov 2021

New research finds disturbing lack of crucial blood cancer medication

New research in the November 2021 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA).

16 Nov 2021

NanoTCE technology shows promise for treatment of acute myeloid leukemia

Oncotarget published "Nanoparticle T cell engagers for the treatment of acute myeloid leukemia" which reported that Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%.

12 Nov 2021

Drug combination highly effective in children with standard- and high-risk acute promyelocytic leukemia

A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.

11 Nov 2021

Researchers identify safety concerns with neuroblastoma candidate drug

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.

9 Nov 2021

Interferon treatment coupled with bone marrow transplant reduces risk of leukemia recurrence

Researchers at the University of Michigan Health Rogel Cancer Center have identified a drug that, when given along with a bone marrow transplant, drops the risk of leukemia recurring by 20% among the high-risk patients.

21 Oct 2021

Research may lead to breakthroughs in combating cancer drug resistances

New research has revealed the differences in mechanism behind cancer’s resistance to the major class of anti-cancer drugs known as nucleoside analogues.

20 Oct 2021

Antiviral activity of wheat germ Agglutinin against SARS-CoV-2

A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.

4 Oct 2021

Novel small-molecule therapy shows promise against deadly pediatric leukemia

Mount Sinai researchers have developed a therapy that shows promise against a deadly pediatric leukemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September.

29 Sep 2021

Scientists discover novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences to treat FLT3-ITD-positive acute myeloid leukemia (AML).

27 Sep 2021

New study clears a pharmacologic hurdle in developing molecularly targeted therapies for AML

New research from Johns Hopkins Kimmel Cancer Center investigators shows why some drugs in clinical trials for treating a form of acute myeloid leukemia (AML) often fail and demonstrates a way to restore their effectiveness.

27 Sep 2021

Researchers discover potential Achilles heel of pediatric acute myeloid leukemia

Researchers at Baylor College of Medicine and Texas Children's Hospital have uncovered a potential Achilles heel of acute myeloid leukemia (AML) in children that could lead to new treatments for this devastating disease.

23 Sep 2021

GammaDelta Therapeutics initiates first-in-human phase 1 trial of GDX012 for the treatment of acute myeloid leukemia

GammaDelta Therapeutics Ltd., a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukemia.

17 Sep 2021

RNF5 protein plays an unusual role in acute myeloid leukemia, study shows

A new study led by scientists at Sanford Burnham Prebys has shown that the protein RNF5 plays an unusual role in acute myeloid leukemia (AML).

13 Sep 2021

High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia

A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a highly aggressive cancer.

12 Sep 2021

CIRM approves a trio of awards for new stem cell-based projects

The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS).

25 Aug 2021

CRISPR screening tool pinpoints new therapeutic target to treat acute myeloid leukemia

A CRISPR screening tool identified a new therapeutic target to treat acute myeloid leukemia (AML) that has the potential to leave patients with fewer side effects than current approaches, according to a new study from Penn Medicine published online in Molecular Cell.

18 Aug 2021

Iron chelating properties of eltrombopag in pediatric acute myeloid leukemia

Oncotarget published "Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia" which reported that the standard treatment for pediatric AML currently consists in a combination of cytarabine and antracycline.

9 Aug 2021